Categories
Pediatric Cancer

Poverty and Childhood Cancer Outcomes: A Novel Intervention Target [Video]

Poverty and Childhood Cancer Outcomes: A Novel Intervention Target

One in six children diagnosed with cancer in the United States lives in poverty, and despite uniform treatment in clinical trials, poverty-exposed children are more likely to relapse compared to children who are not exposed to poverty. Dana-Farber Cancer Institute seeks to improve childhood cancer outcomes by investigating poverty as a risk factor for relapse and developing novel poverty-targeted interventions. Listen to a presentation from Dana-Farber’s Kira Bona, MD, MPH, about her lab’s work to identify and alleviate poverty-associated outcome disparities in childhood cancers. The event is hosted by Joanne Wolfe, MD, MPH.

Watch/Read More
Categories
Pediatric Cancer

Childhood Cancer Services in Africa: Gaps, Inequalities and Solutions [Video]

At the 2021 London Global Cancer Week, SIOP hosted a session called “Childhood Cancer Services in Africa: Gaps, Inequalities and Solutions” featuring a Keynote Speech by H. E. Dr. Zainab Shinkafi-Bagudu of Nigeria. The Session Program includes:Opening Remarks• “A parent’s view of how SIOP can help children with cancer in Africa,” Neil Ranasinghe, Childhood Cancer Parent Advocate, UK• “Introduction and setting the scene in Africa,” Joyce Kambugu, Uganda Cancer Institute and President, SIOP AfricaKeynote Speaker• “Introducing H. E. Dr. Zainab Shinkafi-Bagudu, Keynote Speaker”, Kathy Pritchard-Jones, UK• “Prioritising Childhood cancer in the global cancer agenda,” H.E. Dr. Zainab Shinkafi-Bagudu, First Lady of Kebbi State, Nigeria and CEO of Medicaid Cancer Foundation Childhood Cancer Care in Africa• “African Paediatric Oncology Nurses Making a Difference – Evaluation of the My Child Matters (Sanofi Espoir Foundation) nursing awards in Africa,” Julia Challinor, SIOP Secretary General, USA• “The SIOP Global Mapping project in Africa – Methodology and Key Results,” Jennifer Geel, Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand, South Africa• “Importance of Paediatric Oncology Nursing,” Glenn Mbah, Cameroon Baptist Convention Health Services, Cameroon • “The Power of Partnerships,” Laila Hessissen, Immediate Past-President of SIOP Africa, Morocco

Categories
Pediatric Cancer

Challenges in antibody therapy for pediatric cancer [Video]

Lamia Samrin-Balch, MRPharmS PGDip, Independent Prescriber Pharmacist, MSc Clinical Oncology, Great Ormond Street Hospital, London, UK, highlights some of the challenges associated with treatment with antibodies such as blinatumomab and dinutuximab in pediatric patients. Since antibodies are given continuously over long periods of time, it is important to ensure that parents can use at home infusion pumps and that patients are carefully monitored. In addition, immunotherapy is associated with unpleasant side effects, in particular with dinutuximab where patients often experience pain, blood pressure changes and mobility issues. Nevertheless, the quality of life (QoL) of pediatric patients treated with immunotherapy should be significantly better than in patients treated with chemotherapy. This interview took place at the BOPA 2021 virtual meeting.

Categories
Pediatric Cancer

What is Neuroblastoma? An insightful overview from Daniel Morgenstern. Daniel Morgenstern is a Staff Oncologist at Hospital for Sick Children, Toronto and Assistant Professor at the University of Toronto. He originally qualified in the UK where he was an academic clinical lecturer at UCL Institute of Child Health, trained in drug development at the Royal Marsden Hospital Sutton and was the first Sears Foundation / Garron Cancer Centre Fellow in Neuroblastoma at Hospital for Sick Children. He subsequently worked as a consultant in pediatric oncology at Great Ormond Street Hospital where he was clinical lead for the neuroblastoma and autograft programs, and an active member of the European neuroblastoma consortium SIOPEN.Dr. Morgenstern moved back to SickKids, Toronto in 2016 as Director of the New Agent and Innovative Therapy (NAIT) and Therapeutic mIBG Programs, and co-lead of the neuroblastoma service. Dr Morgenstern’s clinical activities are focussed on neuroblastoma and solid tumor patients participating in early phase clinical trials. His research interests are in early phase trials and, in particular, the use of immune checkpoint inhibitors in pediatric cancers and the development of precision medicine approaches for pediatric solid tumors. He is a member of the study committee for the current COG trial for relapsed/refractory HR neuroblastoma, an active member of the INRG group and is leading the first clinical trial of the Pediatric Cancer Immunotherapy Trials Network (Ped-CITN). At the Hospital for Sick Children, he is medical director of the oncology and BMT/cellular therapy clinical trials support unit. Source: Neuroblastoma Australia Family Conference 2021